FDA Says Johnson & Johnson Covid-19 Vaccine Meets Requirements for Emergency Use Authorization | CNN

What you should know about the Johnson & Johnson vaccine 0:56

(CNN) -

The Johnson & Johnson vaccine against covid-19 met the requirements for authorization for emergency use, according to an analysis published Wednesday by the US Food and Drug Administration (FDA).

Johnson & Johnson vaccine efficacy against moderate to severe / critical COVID-19 in all geographic areas was 66.9% at least 14 days after single-dose vaccination and 66.1% at least 28 days post-vaccination, according to a new analysis intended to report to the FDA's Advisory Committee on Vaccines and Related Biologics.

LOOK: Pfizer, Moderna and Johnson & # 038;

Johnson Commits to Manufacturing 240 Million Doses of Covid-19 Vaccines for the U.S. by End of March

"No specific safety concerns were identified in the subgroup analyzes for age, race, ethnicity, medical comorbidities, or previous SARS-CoV-2 infection," the analysis said.

In an informational document, the FDA said it has reviewed the vaccine data and determined that it is "consistent with the recommendations set forth in the FDA's Authorization of Emergency Use of Vaccines to Prevent COVID-19 guidelines."

An independent group of FDA advisers, the Advisory Committee on Vaccines and Related Biologics, will consider the documents and make a recommendation on whether to authorize vaccination against COVID-19.

The committee meets on Friday.

advertising

MIRA: Which countries have vaccinated the most in South America?

The advancement map, nation by nation

Vaccine